ESMO 2023 GI Cancer Highlights - Codebreak300, CABINET, GASTFOX 

In discussion with Dr. Rachna Shroff, covering the ESMO 2023 GI Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. Shroff:
- Codebreak300 - Sotorasib plus Panitumumab in KRAS G12C-Mutated Metastatic Colorectal Cancer
- CABINET - Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus
- GASTFOX - Evaluate FOLFOX With or Without Docetaxel (TFOX) as First Line Chemotherapy for Locally Advanced or Metastatic Esophago-Gastric Carcinoma
#ESMO #PrecisionMedicine #GICancer #2023 #cancer #oncology #oncbrothers
Website: www.oncbrothers...
Twitter: / oncbrothers
Contact us at info@oncbrothers.com